EUVIMEDOntdek EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review

Lisette Coye, Marisa A Jones, Georgeen Gaza-Bulseco, Carmelata Chitikila, Severine Clavier iD, Delphine Fougeron, Christine Grimaldi iD, Karen Hurkmans, Richard Hutchinson iD, Brenda Kellogg, Xinrong Liu, Nisha Palackal iD and 8 more

Biotechnology and Bioengineering · 2025-11 · 122 (11) · 3229-3248

DOI: 10.1002/bit.70029 ↗

At a glance

Übersichtsarbeit in Biotechnology and Bioengineering, published online on 2025-08-04. Written by Lisette Coye and 19 co-authors. Institution: Pfizer Inc., Pharmaceutical Sciences, Bothell, Washington, USA. Major MEDLINE topics: Biological Products, Drug Industry, Patient Safety, Drug Contamination. Cited 18 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Financial support for this manuscript was provided by BioPhorum Operations Group..

SamenvattingSubjectsBibliografische gegevensCiteRelated studies

Abstract (original language)

Host cell proteins (HCP) are process‐related impurities that can co‐purify with therapeutic proteins. Some HCP impurities potentially can have an impact on patient safety (immunogenicity or toxicity), efficacy, and/or product quality. It is important to reduce the levels of HCP impurities with a well‐controlled manufacturing process and to monitor levels with a suitable analytical assay. Biopharmaceutical companies are now routinely using mass spectrometry to identify HCPs which are present in process intermediates and potentially in bulk drug substances and using the data to make decisions to continuously improve their processes and mitigate the potential risk to patients. Some companies perform identification of HCPs starting from the nonclinical stage of development, while others perform HCP identification at later stages or as a part of root cause analysis for identified HCP ELISA‐related issues, process, and product quality or safety concerns. No matter the approach, a comprehensive risk assessment framework for identified HCPs is needed to support decision‐making during development and is expected by regulators to ensure a safe and efficacious drug product. In this paper the BioPhorum Development Group HCP Workstream has brought together a team of industry experts to build upon existing risk assessment frameworks (e.g., de Zafra et al., 2015) and developed recommendations for assessment of clinical safety risks upon identification of individual HCPs, incorporating regulatory considerations and industry experience and using a real‐world case study to illustrate the use of the updated frameworks. Key recommendations include conducting clinical risk assessment alongside product quality risk assessment following individual HCP identification and quantitation; focusing on biological activity and immunogenicity for any HCPs of concern; and communicating and collaborating effectively across functions to enable a comprehensive risk assessment.

Subjects

MeSH terms (MEDLINE)

Biological ProductsDrug IndustryPatient SafetyDrug ContaminationRisk AssessmentHumans

Author keywords

MS/HCP‐MSPLBL2clinical safety riskhigh‐risk HCPshost cell proteinsimmunogenicityrisk assessment

Substances

Biological Products

Authors and institutions

  • Pfizer Inc., Pharmaceutical Sciences, Bothell, Washington, USA.
  • GSK, Collegeville, Pennsylvania, USA.
  • AbbVie Bioresearch Center, Analytical Development, Worcester, Massachusetts, USA.
  • Johnson & Johnson, Therapeutics Development and Supply, Analytical Development, Malvern, Pennsylvania, USA.
  • Sanofi R&D, BioAnalytics, Global CMC Development, Vitry-sur-seine, France.
  • Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.

ORCID profiles: Severine Clavier, Christine Grimaldi, Richard Hutchinson, Nisha Palackal, Thomas Waerner, Fengqiang Wang, Sapphire Sloan, Christina Zuch de Zafra

Funding

  • Financial support for this manuscript was provided by BioPhorum Operations Group.

Cite

APA

Coye, L., Jones, M. A., Gaza-Bulseco, G., Chitikila, C., Clavier, S., Fougeron, D., Grimaldi, C., Hurkmans, K., Hutchinson, R., Kellogg, B., Liu, X., Palackal, N., Tank, M., Valax, P., Waerner, T., Wang, F., Zhang, Y., Zhao, Y., Sloan, S., & de Zafra, C. Z. (2025). Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review. Biotechnology and Bioengineering, 122(11), 3229-3248. https://doi.org/10.1002/bit.70029

Vancouver

Coye L, Jones MA, Gaza-Bulseco G, Chitikila C, Clavier S, Fougeron D, et al. Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review. Biotechnology and Bioengineering. 2025;122(11):3229-3248. doi:10.1002/bit.70029

BibTeX
@article{Coye2025,
  author = {Coye, Lisette and Jones, Marisa A and Gaza-Bulseco, Georgeen and Chitikila, Carmelata and Clavier, Severine and Fougeron, Delphine and Grimaldi, Christine and Hurkmans, Karen and Hutchinson, Richard and Kellogg, Brenda and Liu, Xinrong and Palackal, Nisha and Tank, Mahima and Valax, Pascal and Waerner, Thomas and Wang, Fengqiang and Zhang, Ying and Zhao, Yiwei and Sloan, Sapphire and de Zafra, Christina Zuch},
  title = {Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review},
  journal = {Biotechnology and Bioengineering},
  year = {2025},
  volume = {122},
  number = {11},
  pages = {3229--3248},
  doi = {10.1002/bit.70029}
}
Start for free →